Phase 2 Study of TD-9855 to Treat Fibromyalgia
Recruiting in Palo Alto (17 mi)
+33 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Theravance Biopharma
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
Research Team
MM
Medical Monitor
Principal Investigator
Theravance Biopharma
Eligibility Criteria
Inclusion Criteria
• American College of Rheumatology (ACR) Diagnostic Criteria for Fibromyalgia (FM)
Informed consent
18 to 65 years of age
See 4 more
Treatment Details
Interventions
- TD-9855 (N/A)
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: TD-9855 Group 2Experimental Treatment1 Intervention
Group 2 to be dosed with TD-9855
Group II: TD-9855 Group 1Experimental Treatment1 Intervention
Group 1 to be dosed with TD-9855
Group III: PlaceboPlacebo Group1 Intervention
Group to be dosed with Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Theravance Biopharma
Lead Sponsor
Trials
74
Recruited
8,600+
Rick E. Winningham
Theravance Biopharma
Chief Executive Officer since 2014
Bachelor's degree in Economics from Southern Methodist University
Laurie Smaldone Alsup
Theravance Biopharma
Chief Medical Officer since 2018
MD from McGill University